

# Peter K Kaiser

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/60242/publications.pdf>

Version: 2024-02-01

167  
papers

22,489  
citations

28272

55  
h-index

8393

147  
g-index

178  
all docs

178  
docs citations

178  
times ranked

8841  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ranibizumab for Neovascular Age-Related Macular Degeneration. <i>New England Journal of Medicine</i> , 2006, 355, 1419-1431.	27.0	5,190
2	Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration. <i>New England Journal of Medicine</i> , 2006, 355, 1432-1444.	27.0	3,221
3	Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. <i>Ophthalmology</i> , 2012, 119, 2537-2548.	5.2	1,947
4	Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study. <i>Ophthalmology</i> , 2009, 116, 57-65.e5.	5.2	1,179
5	The International Vitreomacular Traction Study Group Classification of Vitreomacular Adhesion, Traction, and Macular Hole. <i>Ophthalmology</i> , 2013, 120, 2611-2619.	5.2	855
6	Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration. <i>Ophthalmology</i> , 2014, 121, 193-201.	5.2	693
7	Intravitreal Aflibercept for Diabetic Macular Edema. <i>Ophthalmology</i> , 2014, 121, 2247-2254.	5.2	668
8	Intravitreal Aflibercept for Diabetic Macular Edema. <i>Ophthalmology</i> , 2015, 122, 2044-2052.	5.2	451
9	Synergistic effects of HIV coat protein and NMDA receptor-mediated neurotoxicity. <i>Neuron</i> , 1991, 7, 111-118.	8.1	415
10	Acute endophthalmitis following intravitreal triamcinolone acetonide injection. <i>American Journal of Ophthalmology</i> , 2003, 136, 791-796.	3.3	400
11	Ranibizumab for Predominantly Classic Neovascular Age-related Macular Degeneration: Subgroup Analysis of First-year ANCHOR Results. <i>American Journal of Ophthalmology</i> , 2007, 144, 850-857.e4.	3.3	348
12	Optical Coherence Tomographic Patterns of Diabetic Macular Edema. <i>American Journal of Ophthalmology</i> , 2006, 142, 405-412.e1.	3.3	240
13	Angiographic and Optical Coherence Tomographic Results of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2007, 114, 1868-1875.e4.	5.2	204
14	The Prospective Intraoperative and Perioperative Ophthalmic Imaging With Optical Coherence Tomography (PIONEER) Study: 2-Year Results. <i>American Journal of Ophthalmology</i> , 2014, 158, 999-1007.e1.	3.3	181
15	Macular traction detachment and diabetic macular edema associated with posterior hyaloidal traction. <i>American Journal of Ophthalmology</i> , 2001, 131, 44-49.	3.3	171
16	Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis). <i>Transactions of the American Ophthalmological Society</i> , 2009, 107, 311-24.	1.4	168
17	RETINAL PIGMENT EPITHELIAL TEARS AFTER INTRAVITREAL BEVACIZUMAB INJECTION FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2007, 27, 541-551.	1.7	160
18	Determination of Feasibility and Utility of Microscope-Integrated Optical Coherence Tomography During Ophthalmic Surgery. <i>JAMA Ophthalmology</i> , 2015, 133, 1124.	2.5	158

#	ARTICLE	IF	CITATIONS
19	Neovascular Age-Related Macular Degeneration. <i>Drugs</i> , 2008, 68, 1029-1036.	10.9	155
20	Treatment strategies and visual acuity outcomes in chronic postoperative propionibacterium acnes endophthalmitis11The authors have no proprietary interest in any products or procedure described in this article.. <i>Ophthalmology</i> , 1999, 106, 1665-1670.	5.2	147
21	Optical Coherence Tomography 3: Automatic Delineation of the Outer Neural Retinal Boundary and Its Influence on Retinal Thickness Measurements. , 2004, 45, 2399.		139
22	Antivascular Endothelial Growth Factor Agents and Their Development: Therapeutic Implications in Ocular Diseases. <i>American Journal of Ophthalmology</i> , 2006, 142, 660-668.e1.	3.3	132
23	Intraoperative optical coherence tomography using the RESCAN 700: preliminary results from the DISCOVER study. <i>British Journal of Ophthalmology</i> , 2014, 98, 1329-1332.	3.9	131
24	Cytomegalovirus Retinitis After Fluocinolone Acetonide (Retisertâ,,ç) Implant. <i>American Journal of Ophthalmology</i> , 2007, 143, 334-335.	3.3	125
25	Evaluation of Injection Frequency and Visual Acuity Outcomes for Ranibizumab Monotherapy in Exudative Age-related Macular Degeneration. <i>Ophthalmology</i> , 2009, 116, 1740-1747.	5.2	124
26	Macular translocation for subfoveal choroidal neovascularization in age-related macular degeneration: a prospective study. <i>American Journal of Ophthalmology</i> , 1999, 128, 135-146.	3.3	118
27	Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2012, 119, 1001-1010.	5.2	115
28	Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome. <i>British Journal of Ophthalmology</i> , 2014, 98, 356-360.	3.9	115
29	Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. <i>American Journal of Ophthalmology</i> , 2005, 139, 290-294.	3.3	107
30	OPTICAL COHERENCE TOMOGRAPHYâ€MEASURED PIGMENT EPITHELIAL DETACHMENT HEIGHT AS A PREDICTOR FOR RETINAL PIGMENT EPITHELIAL TEARS ASSOCIATED WITH INTRAVITREAL BEVACIZUMAB INJECTIONS. <i>Retina</i> , 2010, 30, 203-211.	1.7	106
31	UTILITY OF INTRAOPERATIVE OPTICAL COHERENCE TOMOGRAPHY DURING VITRECTOMY SURGERY FOR VITREOMACULAR TRACTION SYNDROME. <i>Retina</i> , 2014, 34, 1341-1346.	1.7	106
32	Chest computerized tomography in the evaluation of uveitis in elderly women. <i>American Journal of Ophthalmology</i> , 2002, 133, 499-505.	3.3	103
33	A Phase 1 Study of KH902, a Vascular Endothelial Growth Factor Receptor Decoy, for Exudative Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2011, 118, 672-678.	5.2	101
34	INTRASURGICAL DYNAMICS OF MACULAR HOLE SURGERY. <i>Retina</i> , 2014, 34, 213-221.	1.7	100
35	NOVEL MICROARCHITECTURAL DYNAMICS IN RHEGMATOGENOUS RETINAL DETACHMENTS IDENTIFIED WITH INTRAOPERATIVE OPTICAL COHERENCE TOMOGRAPHY. <i>Retina</i> , 2013, 33, 1428-1434.	1.7	97
36	A Phase I Study of Intravitreal Vascular Endothelial Growth Factor Trap-Eye in Patients with Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2009, 116, 2141-2148.e1.	5.2	96

#	ARTICLE	IF	CITATIONS
37	A Comparison of Pressure Patching versus No Patching for Corneal Abrasions due to Trauma or Foreign Body Removal. <i>Ophthalmology</i> , 1995, 102, 1936-1942.	5.2	94
38	Comparison of Spectral-Domain versus Time-Domain Optical Coherence Tomography in Management of Age-Related Macular Degeneration with Ranibizumab. <i>Ophthalmology</i> , 2009, 116, 947-955.	5.2	94
39	Methionine Dependence of Cancer. <i>Biomolecules</i> , 2020, 10, 568.	4.0	92
40	Evaluation of Wound Closure in Oblique 23-gauge Sutureless Sclerotomies With Visante Optical Coherence Tomography. <i>American Journal of Ophthalmology</i> , 2009, 147, 101-107.e1.	3.3	89
41	Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Pattern Scan Laser Versus Argon Laser. <i>American Journal of Ophthalmology</i> , 2012, 153, 137-142.e2.	3.3	88
42	The DISCOVER Study 3-Year Results. <i>Ophthalmology</i> , 2018, 125, 1014-1027.	5.2	88
43	OCT-BASED INTERPRETATION OF THE VITREOMACULAR INTERFACE AND INDICATIONS FOR PHARMACOLOGIC VITREOLYSIS. <i>Retina</i> , 2013, 33, 2003-2011.	1.7	86
44	VIP-mediated increase in cAMP prevents tetrodotoxin-induced retinal ganglion cell death in vitro. <i>Neuron</i> , 1990, 5, 373-381.	8.1	76
45	Retinal and choroidal vascular occlusion after posterior sub-tenon triamcinolone injection. <i>American Journal of Ophthalmology</i> , 2002, 134, 132-134.	3.3	76
46	EVALUATION OF WOUND CLOSURE USING DIFFERENT INCISION TECHNIQUES WITH 23-GAUGE AND 25-GAUGE MICROINCISION VITRECTOMY SYSTEMS. <i>Retina</i> , 2008, 28, 242-248.	1.7	75
47	Optical coherence tomography imaging of macular oedema. <i>British Journal of Ophthalmology</i> , 2014, 98, ii24-ii29.	3.9	74
48	A Study of Topical Nonsteroidal Anti-inflammatory Drops and No Pressure Patching in the Treatment of Corneal Abrasions. <i>Ophthalmology</i> , 1997, 104, 1353-1359.	5.2	68
49	Dynamic Evaluation of Sutureless Vitrectomy Wounds: An Optical Coherence Tomography and Histopathology Study. <i>Ophthalmology</i> , 2008, 115, 2221-2228.	5.2	68
50	Presumed Sterile Endophthalmitis Following Intravitreal Triamcinolone Acetonide Injection. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2005, 36, 24-29.	0.7	68
51	Occlusive vasculitis in a patient with concomitant west Nile virus infection. <i>American Journal of Ophthalmology</i> , 2003, 136, 928-930.	3.3	67
52	Choroidal Hemangioma. <i>Ophthalmology Clinics of North America</i> , 2005, 18, 151-161.	1.8	67
53	Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. <i>American Journal of Ophthalmology</i> , 2003, 135, 343-350.	3.3	65
54	Verteporfin photodynamic therapy of six eyes with retinal capillary haemangioma. <i>Acta Ophthalmologica</i> , 2010, 88, e334-40.	1.1	64

#	ARTICLE	IF	CITATIONS
55	A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis. <i>British Journal of Ophthalmology</i> , 2014, 98, i22-i27.	3.9	64
56	3D Spectral Domain Optical Coherence Tomography Findings in Choroidal Tumors. <i>European Journal of Ophthalmology</i> , 2011, 21, 271-275.	1.3	59
57	Sensing and Signaling of Methionine Metabolism. <i>Metabolites</i> , 2021, 11, 83.	2.9	56
58	Comprehensive Review of Ocular and Systemic Safety Events with Intravitreal Aflibercept Injection in Randomized Controlled Trials. <i>Ophthalmology</i> , 2016, 123, 1511-1520.	5.2	54
59	Brolicizumabâ€”early real-world experience: BREW study. <i>Eye</i> , 2021, 35, 1045-1047.	2.1	54
60	Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 585-591.	1.8	53
61	FEASIBILITY OF A NOVEL REMOTE DAILY MONITORING SYSTEM FOR AGE-RELATED MACULAR DEGENERATION USING MOBILE HANDHELD DEVICES. <i>Retina</i> , 2013, 33, 1863-1870.	1.7	50
62	Membrane Peeling-Induced Retinal Alterations on Intraoperative OCT in Vitreomacular Interface Disorders From the PIONEER Study. , 2015, 56, 7324.		50
63	OUTCOME OF FLUOCINOLONE ACETONIDE IMPLANT (RETISERTâ„¢) REIMPLANTATION FOR CHRONIC NONINFECTIOUS POSTERIOR LIVEITIS. <i>Retina</i> , 2008, 28, 1280-1288.	1.7	48
64	A Novel Segmentation Algorithm for Volumetric Analysis of Macular Hole Boundaries Identified with Optical Coherence Tomography. , 2013, 54, 163.		48
65	Ocular manifestations of West Nile Virus. <i>Current Opinion in Ophthalmology</i> , 2004, 15, 537-540.	2.9	46
66	Higher-Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal Fluid Index. <i>Ophthalmology Retina</i> , 2019, 3, 1056-1066.	2.4	44
67	Global approaches to understanding ubiquitination. <i>Genome Biology</i> , 2005, 6, 233.	9.6	43
68	Emerging treatments for wet age-related macular degeneration. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 157-164.	2.4	43
69	SAFETY PROFILE OF OCRIPLASMIN FOR THE PHARMACOLOGIC TREATMENT OF SYMPTOMATIC VITREOMACULAR ADHESION/TRACTION. <i>Retina</i> , 2015, 35, 1111-1127.	1.7	43
70	Clinical impact of the worldwide shortage of verteporfin (VisudyneÂ®) on ophthalmic care. <i>Acta Ophthalmologica</i> , 2022, 100, .	1.1	42
71	Ranibizumab for age-related macular degeneration. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 371-381.	3.1	39
72	Aflibercept in wet age-related macular degeneration: a perspective review. <i>Therapeutic Advances in Chronic Disease</i> , 2012, 3, 153-161.	2.5	39

#	ARTICLE	IF	CITATIONS
73	OCT Angiography and Ellipsoid Zone Mapping of Macular Telangiectasia Type 2 From the AVATAR Study. , 2017, 58, 3683.		39
74	Factors Associated With Persistent Subfoveal Fluid and Complete Macular Hole Closure in the PIONEER Study. Investigative Ophthalmology and Visual Science, 2015, 56, 1141-1146.	3.3	38
75	Review of gene therapies for age-related macular degeneration. Eye, 2022, 36, 303-311.	2.1	38
76	Sterile Endophthalmitis after Intravitreal Triamcinolone: A Possible Association with Uveitis. American Journal of Ophthalmology, 2007, 144, 50-54.e1.	3.3	37
77	Predictive factors for short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema: an optical coherence tomography study. British Journal of Ophthalmology, 2007, 91, 761-765.	3.9	36
78	Stereotactic low-voltage x-ray irradiation for age-related macular degeneration. British Journal of Ophthalmology, 2011, 95, 185-188.	3.9	36
79	Clinical Characteristics and Outcomes of Eyes with Intraocular Inflammation after Brolocizumab: Post Hoc Analysis of HAWK and HARRIER. Ophthalmology Retina, 2022, 6, 97-108.	2.4	36
80	The Developing Regorafenib Eye drops for neovascular Age-related Macular degeneration (DREAM) study: an open-label phase II trial. British Journal of Clinical Pharmacology, 2019, 85, 347-355.	2.4	35
81	Intraocular Pressure Outcome of Patients with Fluocinolone Acetonide Intravitreal Implant for Noninfectious Uveitis. Ophthalmology, 2011, 118, 1927-1931.	5.2	34
82	A novel mutation in the RDS/Peripherin gene causes adult-onset foveomacular dystrophy. American Journal of Ophthalmology, 2003, 135, 213-218.	3.3	33
83	Fourier domain optical coherence tomographic and auto-fluorescence findings in indeterminate choroidal melanocytic lesions. British Journal of Ophthalmology, 2010, 94, 474-478.	3.9	33
84	Current phase 1/2 research for neovascular age-related macular degeneration. Current Opinion in Ophthalmology, 2015, 26, 188-193.	2.9	33
85	Verteporfin ocular photodynamic therapy. Expert Opinion on Pharmacotherapy, 2004, 5, 195-203.	1.8	32
86	Verteporfin therapy in combination with triamcinolone: published studies investigating a potential synergistic effect. Current Medical Research and Opinion, 2005, 21, 705-713.	1.9	30
87	Outcomes of Intraoperative OCT-Assisted Epiretinal Membrane Surgery from the PIONEER Study. Ophthalmology Retina, 2018, 2, 263-267.	2.4	30
88	&lt;p&gt;Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date&lt;/p&gt;. Clinical Ophthalmology, 2020, Volume 14, 1349-1355.	1.8	30
89	Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration. Ophthalmology, 2022, 129, 54-63.	5.2	30
90	Optic nerve head neovascularization in a patient with inactive cytomegalovirus retinitis and immune recovery. American Journal of Ophthalmology, 1998, 126, 318-320.	3.3	29

#	ARTICLE	IF	CITATIONS
91	Long-term Safety and Visual Outcome of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration. <i>Ophthalmology Retina</i> , 2017, 1, 304-313.	2.4	29
92	A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis. <i>Clinical Ophthalmology</i> , 2015, 9, 1759.	1.8	28
93	Skp, Cullin, F-box (SCF)-Met30 and SCF-Cdc4-Mediated Proteolysis of CENP-A Prevents Mislocalization of CENP-A for Chromosomal Stability in Budding Yeast. <i>PLoS Genetics</i> , 2020, 16, e1008597.	3.5	28
94	Longitudinal Assessment of Ellipsoid Zone Integrity, Subretinal Hyperreflective Material, and Subretinal Pigment Epithelium Disease in Neovascular Age-Related Macular Degeneration. <i>Ophthalmology Retina</i> , 2021, 5, 1204-1213.	2.4	28
95	Evaluation of Fluocinolone Acetonide Sustained Release Implant (Retisert) Dissociation during Implant Removal and Exchange Surgery. <i>American Journal of Ophthalmology</i> , 2012, 154, 969-973.e1.	3.3	26
96	Aflibercept for the Treatment of Age-Related Macular Degeneration. <i>Ophthalmology and Therapy</i> , 2013, 2, 89-98.	2.3	26
97	Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trial. <i>Current Medical Research and Opinion</i> , 2009, 25, 1853-1860.	1.9	25
98	The Subretinal Fibrosis and Uveitis Syndrome. <i>International Ophthalmology Clinics</i> , 1996, 36, 145-152.	0.7	24
99	Proteomics Links Ubiquitin Chain Topology Change to Transcription Factor Activation. <i>Molecular Cell</i> , 2019, 76, 126-137.e7.	9.7	24
100	Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2017, 101, 970-975.	3.9	23
101	Retinal vasculitis and posterior pole "œhyopyons" as early signs of acute bacterial endophthalmitis. <i>American Journal of Ophthalmology</i> , 2001, 131, 800-802.	3.3	22
102	Intravitreal triamcinolone as adjunctive treatment to laser panretinal photocoagulation for concomitant proliferative diabetic retinopathy and clinically significant macular oedema. <i>Acta Ophthalmologica</i> , 2008, 86, 105-110.	1.1	22
103	Stereotactic targeting and dose verification for age-related macular degeneration. <i>Medical Physics</i> , 2010, 37, 600-606.	3.0	22
104	Evaluation of Very High- and Very Low-Dose Intravitreal Aflibercept in Patients with Neovascular Age-Related Macular Degeneration. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2012, 28, 581-588.	1.4	21
105	Pipeline therapies for neovascular age related macular degeneration. <i>International Journal of Retina and Vitreous</i> , 2021, 7, 55.	1.9	21
106	Radiation Treatment for Age-Related Macular Degeneration. <i>Seminars in Ophthalmology</i> , 2011, 26, 121-130.	1.6	19
107	Scleral Thickness following Fluocinolone Acetonide Implant (Retisert). <i>Ocular Immunology and Inflammation</i> , 2010, 18, 305-313.	1.8	18
108	Port delivery system: a novel drug delivery platform to treat retinal diseases. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 1571-1576.	5.0	18

#	ARTICLE	IF	CITATIONS
109	Corticosteroid therapy for optic disc neovascularization secondary to chronic uveitis. American Journal of Ophthalmology, 2000, 130, 724-731.	3.3	17
110	Bilateral endogenous endophthalmitis caused by hacek microorganism <sup>11</sup> Financial/proprietary interest: None. American Journal of Ophthalmology, 2002, 133, 144-145.	3.3	17
111	Emerging Therapies for the Treatment of Neovascular Age Related Macular Degeneration. Seminars in Ophthalmology, 2011, 26, 149-155.	1.6	17
112	16-Gy Low-Voltage X-ray Irradiation With Ranibizumab Therapy for AMD: 6-Month Safety and Functional Outcomes. Ophthalmic Surgery Lasers and Imaging Retina, 2011, 42, 468-473.	0.7	17
113	24-Gy Low-Voltage X-Ray Irradiation With Ranibizumab Therapy for Neovascular AMD: 6-Month Safety and Functional Outcomes. Ophthalmic Surgery Lasers and Imaging Retina, 2012, 43, 20-24.	0.7	17
114	Actinobacillus actinomycetemcomitans Endogenous Endophthalmitis: Report of Two Cases and Review of the Literature. Scandinavian Journal of Infectious Diseases, 2003, 35, 133-136.	1.5	16
115	16 Gy low-voltage x-ray irradiation followed by as needed ranibizumab therapy for age-related macular degeneration: 12-month outcomes of a "radiation-first" strategy. British Journal of Ophthalmology, 2012, 96, 1320-1324.	3.9	14
116	Current Best Clinical Practices Management of Neovascular AMD. Journal of Vitreoretinal Diseases, 2017, 1, 294-297.	0.7	14
117	Optical coherence tomography angiography characteristics of choroidal neovascularization requiring varied dosing frequencies in treat-and-extend management: An analysis of the AVATAR study. PLoS ONE, 2019, 14, e0218889.	2.5	14
118	Cystoid puncture for chronic cystoid macular oedema. British Journal of Ophthalmology, 2007, 91, 1062-1064.	3.9	13
119	Ocular complications in patients with lung transplants. British Journal of Ophthalmology, 2011, 95, 1295-1298.	3.9	13
120	Combination therapy for the treatment of neovascular age-related macular degeneration. Current Opinion in Ophthalmology, 2013, 24, 233-238.	2.9	13
121	Role of ranibizumab in management of macular degeneration. Indian Journal of Ophthalmology, 2007, 55, 421.	1.1	13
122	Long-Term Assessment of Macular Atrophy in Patients with Age-Related Macular Degeneration Receiving Anti-Vascular Endothelial Growth Factor. Ophthalmology Retina, 2018, 2, 550-557.	2.4	12
123	Systemic pharmacokinetic/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases. BMJ Open Ophthalmology, 2019, 4, e000185.	1.6	12
124	Risk of bias: why measure it, and how?. Eye, 2022, 36, 346-348.	2.1	12
125	SURGICAL DRAINAGE OF CHRONIC SEROUS RETINAL DETACHMENT ASSOCIATED WITH UVEITIS. Retina, 2008, 28, 282-288.	1.7	11
126	Vitreous wick syndrome a potential cause of endophthalmitis after intravitreal injection of triamcinolone through the pars plana: Author Reply. American Journal of Ophthalmology, 2004, 137, 1160-1161.	3.3	10



#	ARTICLE	IF	CITATIONS
127	Intravitreal aflibercept for neovascular age-related macular degeneration. <i>Immunotherapy</i> , 2013, 5, 121-130.	2.0	9
128	Vitreomacular interface diseases: Diagnosis and management. <i>Taiwan Journal of Ophthalmology</i> , 2014, 4, 63-68.	0.7	9
129	Steroids for choroidal neovascularization. <i>American Journal of Ophthalmology</i> , 2005, 139, 533-535.	3.3	8
130	RETINAL INFILTRATES SECONDARY TO METASTATIC SQUAMOUS CELL CARCINOMA MASQUERADING AS INFECTIOUS RETINITIS. <i>Retinal Cases and Brief Reports</i> , 2014, 8, 333-335.	0.6	8
131	Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration. <i>Core Evidence</i> , 2008, 2, 273-94.	4.7	8
132	The 12- and 24-Month Effects of Intravitreal Ranibizumab, Aflibercept, and Bevacizumab on Intraocular Pressure. <i>Ophthalmology</i> , 2022, 129, 498-508.	5.2	8
133	16 and 24ÂGy Low-voltage X-ray Irradiation With Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration: 12-Month Outcomes. <i>American Journal of Ophthalmology</i> , 2013, 155, 1000-1008.e2.	3.3	7
134	Therapeutic Monoclonal Antibodies and Fragments: Ranibizumab. <i>Developments in Ophthalmology</i> , 2016, 55, 246-251.	0.1	7
135	Cdc48 cofactor Shp1 regulates signal-induced SCF <sup>Met30</sup> disassembly. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 21319-21327.	7.1	7
136	Epiretinal Membrane Surgery Using Intraoperative OCT-Guided Membrane Removal in the DISCOVER Study versus Conventional Membrane Removal. <i>Ophthalmology Retina</i> , 2021, 5, 1254-1262.	2.4	7
137	Advances in AMD Imaging. <i>International Ophthalmology Clinics</i> , 2007, 47, 65-74.	0.7	6
138	TRANS-TAMPONADE OPTICAL COHERENCE TOMOGRAPHY. <i>Retina</i> , 2013, 33, 1172-1178.	1.7	6
139	Prevalence of Outer Retinal Tubulation After Anti-VEGF Therapy for Age-Related Macular Degeneration. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2015, 46, 345-348.	0.7	6
140	Cdc48Ufd1/Npl4 segregase removes mislocalized centromeric histone H3 variant CENP-A from non-centromeric chromatin. <i>Nucleic Acids Research</i> , 2022, 50, 3276-3291.	14.5	6
141	Acute endophthalmitis following intravitreal triamcinolone acetonide injection: Author reply. <i>American Journal of Ophthalmology</i> , 2004, 137, 1167.	3.3	5
142	Anecortave acetate. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 163-169.	4.1	5
143	Branch Vein Occlusion. , 2013, , 1029-1038.		5
144	OCCULT GLOBE PERFORATION DURING MEDIAL CANTHOPEXY. <i>Retinal Cases and Brief Reports</i> , 2018, 12, 231-233.	0.6	4

#	ARTICLE	IF	CITATIONS
145	Uveal vascular tumors. , 2007, , 289-299.		4
146	InternetAdvance: accelerated internet publication of articles and reports at ajo.com. American Journal of Ophthalmology, 2002, 133, 551.	3.3	3
147	STRATEGIES FOR INHIBITING VASCULAR ENDOTHELIAL GROWTH FACTOR. Retina, 2009, 29, S15-S17.	1.7	3
148	OVERVIEW OF RADIATION TRIALS FOR AGE-RELATED MACULAR DEGENERATION. Retina, 2009, 29, S34-S35.	1.7	3
149	Comparison of OCT Angiography Review Strategies to Identify Vascular Abnormalities in the AVATAR Study. Ophthalmology Retina, 2018, 2, 606-612.	2.4	3
150	Diagnostic and Therapeutic Challenges. Retina, 2007, 27, 642-647.	1.7	2
151	Macular thickness fluctuation in neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor. Canadian Journal of Ophthalmology, 2022, 57, 350-356.	0.7	2
152	Radiation therapy in the treatment of exudative age-related macular degeneration. Expert Review of Ophthalmology, 2011, 6, 323-337.	0.6	1
153	Wound Construction. Developments in Ophthalmology, 2014, 54, 71-76.	0.1	1
154	Optical Coherence Tomography Angiography in Eyes with Indeterminate Choroidal Neovascularization. Ophthalmology Retina, 2018, 2, 1107-1117.	2.4	1
155	Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA. Journal of Comparative Effectiveness Research, 2018, 7, 1195-1207.	1.4	1
156	The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review. Journal of Ophthalmology, 2020, 2020, 1-10.	1.3	1
157	Reply to Comment on: Conbercept for Treatment of Neovascular Age-Related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study. American Journal of Ophthalmology, 2020, 215, 154-155.	3.3	1
158	Seeing the patient's perspective: a guide to patient-reported outcome measures and minimal important differences in ophthalmic research. Eye, 2022, , .	2.1	1
159	Anecortave acetate in the treatment of age-related macular degeneration. Expert Review of Ophthalmology, 2006, 1, 135-139.	0.6	0
160	siRNA therapeutics for age-related macular degeneration: promises and pitfalls. Expert Review of Ophthalmology, 2009, 4, 525-535.	0.6	0
161	Complement therapy in dry age-related macular degeneration. Drug Discovery Today: Therapeutic Strategies, 2013, 10, e5-e10.	0.5	0
162	III.D. Vitreo-Macular Adhesion/Traction and Macular Holes: Pseudo, Lamellar, and Full-Thickness. , 2014, , 287-297.		0

#	ARTICLE	IF	CITATIONS
163	Controversies in Using Off-Label Intravitreal Bevacizumab for Patients With Diabetic Macular Edema. JAMA Ophthalmology, 2017, 135, 291.	2.5	0
164	Combination Therapy with Ocular Photodynamic Therapy for Age-Related Macular Degeneration. , 2011, , 99-118.		0
165	Kombinationstherapien zur Behandlung der AMD. , 2011, , 253-268.		0
166	Future therapies. , 2015, , 121-133.		0
167	The clinician's guide to randomized trials: interpretation. Eye, 2022, , .	2.1	0